SUMATRIPTAN AND NAPROXEN SODIUM
Clinical safety rating: avoid
Other 5-HT1 agonists and MAOIs can have additive effects Contraindicated in ischemic heart disease and uncontrolled hypertension.
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of intracranial arteries and inhibiting trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. The combination provides synergistic relief for migraine by targeting both neurogenic inflammation and vasodilation.
| Metabolism | Sumatriptan is metabolized primarily by monoamine oxidase A (MAO-A) to an indoleacetic acid metabolite. Naproxen sodium is metabolized by hepatic CYP enzymes (CYP1A2, CYP2C9) and other pathways, with glucuronidation. |
| Excretion | Sumatriptan: 57% renal (22% unchanged), 38% fecal; Naproxen: 95% renal (mostly as conjugated metabolites, <5% unchanged), <5% fecal. |
| Half-life | Sumatriptan: 2.5 hours (range 2-4 hours); Naproxen: 12-17 hours (mean 14 hours). Clinical context: Sumatriptan half-life supports short dosing interval; Naproxen half-life allows twice-daily dosing for migraine prevention. |
| Protein binding | Sumatriptan: 14-21% (primarily albumin); Naproxen: >99% (albumin, extensively bound). |
| Volume of Distribution | Sumatriptan: 2.4 L/kg (suggests extensive tissue distribution); Naproxen: 0.16 L/kg (confined primarily to plasma and synovial fluid). |
| Bioavailability | Sumatriptan: Oral 15% (due to first-pass metabolism), subcutaneous 96%, intranasal 17%; Naproxen: Oral >95% (nearly complete). |
| Onset of Action | Oral: Sumatriptan 30-60 min, Naproxen 60-120 min; Subcutaneous sumatriptan: 10-15 min; Intranasal sumatriptan: 15-30 min. |
| Duration of Action | Sumatriptan: 2-4 hours (subcutaneous up to 6 hours); Naproxen: up to 12 hours. Clinical note: Combination provides sustained relief for migraine attacks lasting 4-72 hours. |
Sumatriptan 85 mg/naproxen sodium 500 mg orally at onset of migraine; maximum one tablet per 24 hours.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in severe renal impairment (CrCl <30 mL/min); no adjustment recommended for mild to moderate impairment. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C); not recommended in moderate impairment (Child-Pugh class B); no adjustment for mild (Child-Pugh class A). |
| Pediatric use | Not recommended for patients under 18 years due to safety and efficacy not established. |
| Geriatric use | Not recommended in patients ≥65 years due to increased risk of adverse events; no specific dosing adjustments available. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other 5-HT1 agonists and MAOIs can have additive effects Contraindicated in ischemic heart disease and uncontrolled hypertension.
| FDA category | Contraindicated |
| Breastfeeding | Sumatriptan: Excreted in breast milk in low amounts (M/P ratio 4.9); infant dose about 3.5% of maternal weight-adjusted dose; limited data show no adverse effects. Naproxen: Excreted in breast milk (M/P ratio 0.01-0.17); infant dose about 1-2% of maternal dose; use caution in premature infants or with prolonged use due to potential NSAID effects. |
| Teratogenic Risk |
■ FDA Black Box Warning
None
| Common Effects | Chest pain |
| Serious Effects |
["History of coronary artery disease, myocardial infarction, or ischemic heart disease","Coronary vasospasm (Prinzmetal's angina)","Uncontrolled hypertension","Cerebrovascular disease (stroke or transient ischemic attack)","Peripheral vascular disease","Hemiplegic or basilar migraine","Severe hepatic impairment","Third trimester of pregnancy","History of GI bleeding or perforation related to NSAID use","Active peptic ulcer disease","Concurrent use of MAO-A inhibitors or within 2 weeks of discontinuation","Hypersensitivity to sumatriptan, naproxen, or aspirin/other NSAIDs (including aspirin triad)"]
| Precautions | ["Cardiovascular risk: Serious cardiovascular events including myocardial infarction, stroke, and coronary vasospasm, especially in patients with risk factors.","Gastrointestinal risk: NSAID-induced GI bleeding, ulceration, and perforation, particularly in elderly or those with prior GI history.","Hypertension: Elevation in blood pressure, including hypertensive crisis.","Serotonin syndrome: Risk when combined with other serotonergic drugs (e.g., SSRIs, MAOIs).","Renal toxicity: NSAIDs may impair renal function.","Anaphylaxis/allergic reactions: Immediate medical attention required.","Withdrawal headache: Overuse may lead to medication-overuse headache."] |
Loading safety data…
| Sumatriptan: Human data do not show increased risk of major birth defects overall, but limited data in first trimester; animal studies show embryo/fetal toxicity at high doses. Naproxen: NSAIDs should be avoided after 30 weeks gestation due to risk of premature closure of ductus arteriosus and oligohydramnios; avoid in first and second trimesters unless clearly needed due to potential association with cardiac defects and miscarriage. |
| Fetal Monitoring | Monitor for signs of oligohydramnios (ultrasound if prolonged NSAID use), fetal ductus arteriosus constriction (after 30 weeks), maternal bleeding risk, cardiovascular effects (blood pressure, heart rate), and hepatic/renal function. For sumatriptan: monitor for recurrence of migraine symptoms. |
| Fertility Effects | Sumatriptan: No known adverse effects on fertility. Naproxen: NSAIDs may impair female fertility by interfering with ovulation; reversible upon discontinuation. Limited effect on male fertility. |